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Suzanah C. Boyd1, Branka Mijatov1, Gulietta M. Pupo1, Sieu L. Tran1, Kavitha Gowrishankar1,
Heather M. Shaw2, Colin R. Goding2, Richard A. Scolyer3, Graham J. Mann1,3, Richard F. Kefford1,3,
Helen Rizos1 and Therese M. Becker1
Approximately 50% of melanomas require oncogenic B-RAFV600E signaling for proliferation, survival, and
metastasis, and the use of highly selective B-RAF inhibitors has yielded remarkable, although short-term, clinical
responses. Reactivation of signaling downstream of B-RAF is frequently associated with acquired resistance to
B-RAF inhibitors, and the identification of B-RAF targets may therefore provide new strategies for managing
melanoma. In this report, we applied whole-genome expression analyses to reveal that oncogenic B-RAFV600E
regulates genes associated with epithelial–mesenchymal transition in normal cutaneous human melanocytes.
Most prominent was the B-RAF-mediated transcriptional repression of E-cadherin, a keratinocyte–melanoma
adhesion molecule whose loss is intimately associated with melanoma invasion and metastasis. Here we identify
a link between oncogenic B-RAF, the transcriptional repressor Tbx3, and E-cadherin. We show that B-RAFV600E
induces the expression of Tbx3, which potently represses E-cadherin expression in melanocytes and melanoma
cells. Tbx3 expression is normally restricted to developmental embryonic tissues and promoting cell motility,
but it is also aberrantly increased in various cancers and has been linked to tumor cell invasion and metastasis.
We propose that this B-RAF/Tbx3/E-cadherin pathway has a critical role in promoting the metastasis of
B-RAF-mutant melanomas.
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INTRODUCTION
Cutaneous melanoma is a highly aggressive cancer and, until
recently, the majority of patients with visceral metastases had
survival rates of o1 year (Balch et al., 2001). The use of tar-
geted inhibitors, in particular, inhibitors of oncogenic B-RAF,
have produced remarkable, although short-lived, clinical
responses (Flaherty et al., 2010; Falchook et al., 2012).
Developing an effective treatment for metastatic melanoma
therefore remains a major challenge and requires a thorough
understanding of the events occurring downstream of B-RAF.
Constitutively activating mutations affecting the serine/
threonine kinase, B-RAF, predominantely the oncogenic
B-RAFV600E, are found in B50% of metastatic melanomas
(reviewed in Platz et al., 2008). Oncogenic B-RAF signals
through the mitogen-activated protein kinase cascade to
promote the proliferation and survival of transformed melano-
cytes. There is also mounting evidence that oncogenic B-RAF
contributes to tumor aggressiveness by regulating tumor cell
morphology, adhesion, migration, and invasion. Indeed,
B-RAFV600E in human melanoma is associated with loss of
cell cohesion and the upward migration of melanoma cells
into the epidermis (Viros et al., 2008; Broekaert et al., 2010).
Moreover, B-RAFV600E is strongly associated with lymph node
metastasis in papillary thyroid carcinomas (Basolo et al.,
2010), and there is some evidence that this may reflect
altered expressions of extracellular matrix (ECM) genes,
such as integrins, laminin and fibronectin, and epithelial-to-
mesenchymal transition (EMT)-associated adhesion factors
(Nucera et al., 2010; Knauf et al. 2011). EMT involves
disassembly of cellular junctional structures, which character-
istically involve the loss of E-cadherin expression and
accumulation of mesenchymal proteins. Loss of E-cadherin
expression is common in melanoma and has a critical role in
altering melanoma cell interactions and promoting tumor cell
invasion and metastasis (Ikoma et al., 2005; Tucci et al., 2007;
Kreizenbeck et al., 2008). However, how B-RAF regulates an
EMT-like transition in melanoma cells is not known, although
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it presumably involves the activation of transcription
factors able to downregulate adhesion molecules to promote
invasiveness.
Here we applied a genome-wide expression profiling
approach to identify signaling changes downstream of
B-RAFV600E that modulate melanocyte morphology and migra-
tion. As predicted, oncogenic B-RAF signaling altered the
expressions of genes involved in cell morphology, cell adhe-
sion, migration, ECM remodeling, and EMT. Importantly,
we show that B-RAF represses E-cadherin transcription by
promoting the expression of Tbx3. Thus, Tbx3 acts as critical
regulator of oncogenic B-RAF signaling, promoting cell
proliferation, migration, and metastasis by repressing the
transcription of tumor-suppressor genes, including E-cadherin.
RESULTS
Oncogenic B-RAF deregulates genes involved in melanocyte
adhesion and cytoskeleton remodeling
To evaluate the influence of B-RAFV600E signaling on the
transcriptome of primary human melanocytes, B-RAFV600E was
stably transduced into primary melanocytes using lentiviral
vectors coexpressing Copepod green fluorescent protein
(copGFP). Viral titers were selected to provide an efficiency
of infection above 90% and activation of the extracellular
signal–regulated kinase (ERK) pathway that was comparable to
human melanoma cells expressing endogenous B-RAFV600E
(Figure 1). We then performed genome-wide expression
analysis using the high-throughput Illumina HumanRef-6 plat-
form to compare the transcriptome signatures of human
epidermal melanocytes with or without oncogenic
B-RAFV600E. Among the set of 1,650 genes that were differen-
tially expressed (P-value o0.01 from duplicate experiments),
genes involved in integrin-mediated cell adhesion and migra-
tion (P-value 6.3e9), ECM remodeling (P-value 1.7e7),
cytoskeleton remodeling (P-value 2e7), and EMT (P-value
1.480e 3) were highly enriched. As shown in Table 1, this
gene set included many genes involved in cell adhesion
(VEGFA–C, ITGA3, and ITGA5), cytoskeleton remodeling
(EZR, PLAT, and MSN), and ECM remodeling (TIMP1-3, IL8,
and KLK2), including an extensive range of molecules
associated with EMT (AP1, FOSL1, CTGF, and CDH1). Of
particular interest for melanoma progression and metastasis
was the reduction of the E-cadherin transcript (CDH1) upon
B-RAFV600E signaling (Table 1). Consistent with the observed
transcription profile, melanocytes expressing B-RAFV600E show
rounded cell morphology and diminished substrate and cell
adhesion as reported previously (Becker et al., 2010).
B-RAFV600E diminishes E-cadherin expression in melanocytes
To confirm the impact of mutant B-RAFV600E on E-cadherin
transcript expression, we used quantitative real-time PCR
(qRT-PCR) and confirmed that exogenous B-RAFV600E sig-
naling reduced melanocyte E-cadherin transcript levels by
490%, 3 days after transduction (Figure 2a), and B-RAFV600E
repressed the E-cadherin promoter similarly in promoter
reporter assays (data not shown). Moreover, E-cadherin protein
levels were significantly diminished in B-RAFV600E-transduced
normal melanocytes derived from three individuals
(Figure 2b), and E-cadherin protein levels increased when
B-RAFV600E was specifically silenced by short hairpin RNA
(shRNA) or inhibited using the targeted B-RAF inhibitor,
Vemurafenib (PLX4032), in two B-RAFV600E-positive mela-
noma cell lines (NM176 and ME1042) (Figure 2c).
B-RAFV600E upregulates the Tbx3 transcriptional repressor
To define the mechanism by which oncogenic B-RAF sup-
pressed E-cadherin transcription, we reanalyzed our transcrip-
tome arrays for changes in the expression of established
regulators of E-cadherin transcription. Although EMT has
traditionally been associated with the upregulation of the
E-cadherin regulators SLUG and SNAIL (Cano et al., 2000;
Poser et al., 2001; Hajra et al., 2002; Bolos et al., 2003;
Conacci-Sorrell et al., 2003), in melanoma, an additional
tissue-restricted repressor of E-cadherin, Tbx3, has been
identified (Rodriguez et al., 2008). Tbx3, a member of
the T-box family of developmental regulators (Bamshad
et al., 1997; Rowley et al., 2004; Lee et al., 2007; Suzuki
et al., 2008), has been strongly implicated in cancer (Hoek
et al., 2004; Rodriguez et al., 2008; Peres et al., 2010). Indeed,
as shown in Figure 3a, Tbx3 was significantly upregulated
(B10-fold) in melanocytes with B-RAFV600E signaling,
whereas no other known E-cadherin regulator in our Illumina
data set was significantly altered. We confirmed that
B-RAFV600E upregulated Tbx3 transcription using qRT-PCR
analyses (Figure 3b). It is noteworthy that the Tbx3 primers
used in these experiments amplified both splice variants of
Tbx3 (Lee et al., 2007), and the expression of both variants
was elevated by B-RAFV600E (Figure 3c). Moreover, the activity
of the Tbx3 promoter was strongly upregulated by exogenous
B-RAFV600E when measured using promoter reporter assays
(Figure 4a). Consistent with these data, the expression of Tbx3
correlated with B-RAF mutation status in our microarray
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Figure 1. Activity of exogenous B-RAFV600E in human melanocytes. Primary
human melanocytes were infected with lentiviruses encoding B-RAFV600E with
Copepod green fluorescent protein (copGFP) or copGFP alone (control) for
3 days. The expression levels of phosphorylated extracellular signal–regulated
kinase (p-ERK) were compared with those observed in a series of melanoma
cell lines with known B-RAF/N-RAS genotypes (WMM1175: N-RASG13R;
NM39, SKMel28, and ME1042: B-RAFV600E). Ectopic B-RAF expression
was detected by probing for the Myc-tag of B-RAFV600E.
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Table 1. Fold gene expression changes in melanocytes
(V600E/control) presented in common gene ontology
groups
Gene
symbol Protein name
Fold change
(V600Eþ /
control)
Focal adhesion
Jun Transcription factor AP-1 subunit Jun 10.7±1
JunB Transcription factor AP-1 subunit jun-B 9.6±0.8
VEGFA Vascular endothelial growth factor A 7.1±0.7
VEGFC Vascular endothelial growth factor C 5.0±0.1
MAPK8IP3 C-Jun-amino-terminal kinase-interacting
protein 3
4.9±1.3
ITGA5 Integrin a-5 4.2±0.9
GSK3B Glycogen synthase kinase-3 b 3.5±0.7
ZYX Zyxin 3.1±0.4
ACTN4 Alpha-actinin-4 3.0±0.6
ITGB5 Integrin b-5 2.9±0.3
BCAR1 Breast cancer anti-estrogen resistance
protein 1
2.7±0.1
MAP2K1 Dual specificity mitogen-activated protein
kinase kinase 1
2.5±0.3
MAPK1 Mitogen-activated protein kinase 1 2.4±0.2
SRC Proto-oncogene tyrosine-protein kinase Src 2.3±0.5
ITGA3 Integrin a-3 2.3±0.5
CRKL Crk-like protein 2.0±0.0
TLN1 Talin-1 2.0±0.2
ACTN1 a-Actinin-1 1.7±0.3
ITGB1 Integrin b-1 1.5±0.3
PTEN Phosphatidylinositol-3,4,5-trisphosphate 3-
phosphatase and dual-specificity protein
phosphatase PTEN
0.4±0.1
PIK3R2 Phosphatidylinositol 3-kinase regulatory
subunit b
0.4±0.1
PRKCA Protein kinase C a type 0.4±0.1
VEGFB Vascular endothelial growth factor B 0.4±0.1
PRKCB1 Protein kinase C b type 0.3±0.0
COL5A2 Collagen a-2(V) chain 0.3±0.1
PPP1CB Serine/threonine-protein phosphatase PP1-b
catalytic subunit
0.3±0.1
Regulation of actin cytoskeleton/cytoskeleton remodeling
PLAUR Urokinase plasminogen activator surface
receptor
14.6±0.2
EZR Ezrin 8.1±0.0
PLAT Tissue-type plasminogen activator 7.7±0.4
INSIG1 Insulin-induced gene 1 protein 5.4±0.3
RRAS2 Ras-related protein R-Ras2 3.7±1.4
PAK3 Serine/threonine-protein kinase PAK 3 3.4±0.1
MSN Moesin 2.1±0.3
ACTB b-Cytoskeletal actin 0.7±0.2
ACTA2 a-Actin-2 0.5±0.1
Table 1. (Continued )
Gene
symbol Protein name
Fold change
(V600Eþ /
control)
CYFIP2 Cytoplasmic FMR1-interacting protein 2 0.5±0.0
WASF3 Wiskott-Aldrich syndrome protein family
member 3
0.4±0.1
MYH10 Myosin-10 0.3±0.0
Adherens junctions
PVRL2 Poliovirus receptor-related protein 2 2.6±0.3
FERMT3 Fermitin family homolog 3 2.1±0.1
MET Hepatocyte growth factor receptor 0.5±0.0
SNAI2 Zinc-finger protein SNAI2 (SLUG) 0.3±0.0
CDH1 Cadherin-1 (E-cadherin) 0.3±0.1
METTL9 Methyltransferase-like protein 9 0.2±0.0
Cell adhesion molecules
CD82 CD82 molecule 4.9±0.4
CD8A T-cell surface glycoprotein CD8 a chain 4.1±0.2
F11R Junctional adhesion molecule A 3.8±0.1
MPZL1 Myelin protein zero-like protein 1 3.3±0.6
HLA-F HLA class I histocompatibility antigen,
a chain F
2.8±0.1
HLA-B HLA class I histocompatibility antigen, B-7
a chain
2.6±0.1
PVR Poliovirus receptor 2.6±0.3
HLA-A HLA class I histocompatibility antigen, A-1
a chain
2.5±0.4
HLA-G HLA class I histocompatibility antigen,
a chain G
2.4±0.1
CD151 Membrane glycoprotein SFA-1 2.2±0.2
MAGED4 Melanoma-associated antigen 0.4±0.1
CD47 Leukocyte surface antigen CD47 0.3±0.0
Extracellular matrix remodeling
IL8 Interleukin-8 39.9±13.2
HBEGF Heparin-binding EGF-like growth factor 17.0±0.7
Il6 Interleukin-6 9.2±0.4
TIMP3 Metalloproteinase inhibitor 3 4.6±1.6
IGFBP4 Insulin-like growth factor-binding protein 4 3.2±1.2
KLK2 Kallikrein-2 3.0±0.5
TIMP1 Metalloproteinase inhibitor 1 2.2±0.1
MMP12 Macrophage metalloelastase 0.4±0.0
TIMP2 Metalloproteinase inhibitor 2 0.3±0.1
Epithelial–mesenchymal transition
PTGS2 Prostaglandin-endoperoxide synthase 2 56.2±4.3
FOSB Oncogene FOS-B 45.8±1.9
JUN Transcription factor AP-1 subunit Jun 10.7±1.0
Table 1 continued on following page
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analyses of 60 stage III-excised human melanoma lymph node
metastases. In particular, the expression of Tbx3 was signifi-
cantly increased in B-RAF-mutant tumors (Mann–Whitney
P¼0.01; Figure 4b and Table 2). Significantly, we confirmed
that oncogenic B-RAF also promoted the accumulation of
Tbx3 protein as well as the reduction of E-cadherin in three
independent melanocytes strains, and as expected, E-cadherin
repression correlated with N-cadherin accumulation
(Figure 2b). We also confirmed that the B-RAF-mediated
effects on E-cadherin and Tbx3 expression were not because
of B-RAFV600E-induced melanocyte senescence (Scurr et al.,
2010), as the introduction of B-RAFV600E into the NM179
Table 1. (Continued )
Gene
symbol Protein name
Fold change
(V600Eþ /
control)
RPS6KA1 Ribosomal protein S6 kinase 10±1.1
JunB Transcription factor AP-1 subunit jun-B 9.6±0.8
EGR1 Early growth response protein 1 7.7±2.2
CTGF Insulin-like growth factor-binding protein 8 6.3±0.3
FOSL1 FOS-like antigen 1 6.0±1.2
FOS Cellular oncogene c-fos 5.0±0.5
CD8A T-cell surface glycoprotein CD8 a chain 4.1±0.2
TNFRSF1A Tumor necrosis factor receptor type 1 3.9±0.1
MAP2K3 Dual specificity mitogen-activated protein
kinase kinase 3
3.8±1.4
AXIN1 Axis inhibitor 1 3.5±0.0
GSK3B Glycogen synthase kinase-3 b 3.5±0.7
RPS6KA2 Ribosomal protein S6 kinase 3.5±0.7
RPS6KA3 Ribosomal protein S6 kinase 3.0±0.2
MAP2K1 Mitogen-activated protein kinase kinase 1 2.5±0.3
MAPK1 Mitogen-activated protein kinase 1 2.4±0.2
SRC Proto-oncogene tyrosine-protein kinase Src 2.3±0.5
NES Nestin 2.2±0.4
ACVR1 Activin A receptor, type I 1.8±0.2
ITGB1 Integrin b-1 1.5±0.3
ACTB b-Cytoskeletal actin 0.7±0.2
CREB1 cAMP responsive element binding protein 1 0.6±0.1
ACTA2 a-Actin-2 0.5±0.1
STAT1 Signal transducer and activator of
transcription 1
0.5±0.1
MET Hepatocyte growth factor receptor 0.5±0.0
ETS1 v-ets erythroblastosis virus E26 oncogene
homolog 1
0.4±0.1
PIK3R2 Phosphoinositide-3-kinase, regulatory
subunit 2
0.4±0.1
CALD1 Caldesmon 1 0.4±0.2
JAG1 Jagged 1 0.3±0.1
CDH1 Cadherin-1 (E-cadherin) 0.3±0.1
SNAI2 Zinc-finger protein SNAI2 (SLUG) 0.3±0.0
ZEB2 Zinc-finger E-box binding homeobox 2 0.2±0.0
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Figure 2. B-RAFV600E signaling represses E-cadherin. (a) Melanocytes were
infected with lentiviruses encoding B-RAFV600E with Copepod green
fluorescent protein (copGFP) or copGFP alone (control) for 3 days. Total RNA
was analyzed by quantitative real-time PCR (qRT-PCR). E-cadherin transcript
levels in B-RAFV600E-transduced melanocytes were normalized to levels of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or TATA box protein
(TBP) housekeeping genes and expressed relative to normalized E-cadherin
transcript levels in control-transduced cells. (b) Three independent melanocyte
strains and NM179 melanoma cells were infected with lentiviruses encoding
B-RAFV600E with copGFP or copGFP alone (control) for 3 days. Total protein
was immunoblotted for the indicated proteins. (c) B-RAF signaling was
inhibited in the B-RAF-mutant melanoma cell lines, NM176 and ME1042,
using the B-RAFV600E-specific silencing molecule for 5 days or 10mm PLX4032
for 2 days. Total protein was immunoblotted for the indicated proteins.
p-ERK, phosphorylated extracellular signal–regulated kinase; shRNA, short
hairpin RNA.
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melanoma cells (wild-type B-RAF) also regulated the
expression of Tbx3 and E-cadherin (Figure 2b) in the absence
of proliferative arrest (data not shown). Finally, the specific
silencing or inhibition of BRAFV600E expression in the NM176
and ME1042 melanoma cells decreased Tbx3 protein expres-
sion and this correlated with the concomitant increased
E-cadherin (Figure 2c).
B-RAFV600E-mediated Tbx3 upregulation causes E-cadherin
repression
To confirm that Tbx3 was the critical effector of B-RAFV600E-
mediated E-cadherin transcriptional repression in melano-
cytes, we applied two highly specific Tbx3 silencing
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Figure 3. B-RAFV600E regulates Tbx3 expression in melanocytes. Primary
human melanocytes were infected with lentiviruses encoding B-RAFV600E with
Copepod green fluorescent protein (copGFP) or copGFP alone (control) for 3
days. (a) Transcript expression levels of established E-cadherin transcriptional
regulators in B-RAFV600E-transduced melanocytes measured in gene expression
arrays. Transcript levels are expressed relative to control-transduced
melanocytes (indicated by gray line). (b) Total RNA derived from a minimum of
three independent transduction experiments were analyzed by quantitative
real-time PCR (qRT-PCR). Tbx3 transcript levels in B-RAFV600E-transduced
melanocytes were normalized to levels of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) or TATA box protein (TBP) housekeeping genes and
expressed relative to normalized Tbx3 transcript levels in control-transduced
cells. (c) Tbx3 complementary DNA (cDNA) derived from B-RAFV600E or
control-transduced melanocytes was amplified for 25 PCR cycles and products
analyzed using agarose gel electrophoresis.
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Figure 4. B-RAFV600E regulates Tbx3 expression in melanoma. (a) 501mel
melanoma cells were transfected with the human Tbx3 promoter (249 to
þ168 in pGL3basic) or the pGL3 basic vector alone together with 25 or
100 ng of B-RAF wild-type (wt) or V600E expression plasmid. Promoter activity
was derived from the measured luciferase activity normalized to the promoter
activity of pGL3 basic transfected cells. Immunoblotting confirmed similar
expression of the Myc epitope-tagged B-RAF constructs using anti-Myc
antibody. ERK, extracellular signal–regulated kinase. (b) Total RNA from stage
III melanoma lymph node metastasis was analyzed by gene expression arrays.
The relative median Tbx3 transcript expression levels are shown (n¼ 27 B-RAF
wt tumors and n¼ 33 tumors expressing B-RAFV600E). For comparison, the
expression levels of Tbx3 in cultured normal melanocytes transduced to
express control or B-RAFV600E are presented (black asterisk).
Table 2. Expression changes in excised human
melanoma stage III (lymph node) metastases according
to B-RAF status
Wild type B-RAFV600E P-value
Transcript Median LQ/UQ Median LQ/UQ
CDH-1 930.9 29/9,240.7 704.2 72.2/7,004.6 1.0
Tbx3 144.5 38.1/662.7 310.4 25.8/2,166.4 0.01
Abbreviations: LQ, lower quartile; UQ upper quartile.
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molecules. Each silencer was introduced into melanocytes
for 5 days, followed by transduction with oncogenic B-RAF.
The Tbx3 silencers partially suppressed the B-RAF-mediated
induction of Tbx3 and this led to the partial restoration of
E-cadherin expression in the presence of B-RAFV600E
(Figure 5). As expected, E-cadherin transcript levels, when
compared with the expression levels in melanocytes (data not
shown), were universally low in our patient cohort of stage III
lymph node metastatic melanomas. Consequently, although
there was a positive relationship between oncogenic B-RAF
and Tbx3 (see Figure 4b and Table 2), we could not detect
an association between oncogenic B-RAF or Tbx3 with
E-cadherin expression in these samples (Table 2).
B-RAFV600E signaling and Tbx3 promote melanoma cell invasion
To examine the role of the B-RAF/Tbx3/E-cadherin cascade on
melanoma cell invasion, we silenced B-RAFV600E or Tbx3 in
the B-RAF-dependent NM176 and ME1042 melanoma
cells. As expected, suppression of B-RAFV600E decreased the
invasion of both melanoma cell lines through matrigel.
Similarly, silencing Tbx3 expression also markedly diminished
the invasive potential of the NM176 and ME1042 melanoma
cells (Figure 6).
DISCUSSION
B-RAFV600E deregulates many genes involved in cell adhesion,
ECM formation, and cytoskeletal integrity (Nucera et al., 2010;
Knauf et al., 2011). The combined downstream effects suggest
that oncogenic B-RAF promotes EMT and thereby enhances
the migratory and metastatic capacity of the transformed cells.
EMT involves the disassembly of junctional structures typically
through the loss of E-cadherin expression, loss of cellular
polarity, and increased migration. Two studies have shown
that B-RAF signaling is associated with reduced levels
of E-cadherin in breast epithelial and colon cancer cells
(Brummer et al., 2006; Minoo et al., 2007), and we now
report that B-RAFV600E inhibits the transcription of E-cadherin
in human melanocytes and melanoma cells. Although
melanocytes are not epithelial cells, E-cadherin is required
for their critical interaction with keratinocytes. The loss of
E-cadherin produces an EMT-like melanocytic phenotype, is
required for invasion, and is associated with melanoma
progression and metastasis by preventing keratinocyte-
regulation of melanocytes (reviewed in Hsu et al., 2000;
Haass et al., 2005).
Here we provide evidence that Tbx3 is strongly upregulated
by oncogenic B-RAF in human melanocytes and melanoma
cells, which is inhibited by PLX4032 treatment. Furthermore,
we show that Tbx3 upregulation correlated with B-RAF
mutation status in 60 metastatic melanoma samples. These
data from fresh-frozen, uncultured melanoma biopsies support
a recent report showing the increased levels of Tbx3 in B-RAF-
mutant melanoma cell lines (Johansson et al., 2007).
Importantly, we have confirmed that partial depletion of
Tbx3 opposed the suppression of E-cadherin expression by
oncogenic B-RAF in melanocytes, and this has important
implications in melanoma and other cancers including,
ovarian carcinoma, pancreatic cancer, breast cancer, and
cervical cancer, that overexpress Tbx3 (reviewed in Lu et al.
2010). We have shown previously that melanoma progression
is associated with increased expression of Tbx3 protein and,
significantly, silencing of Tbx3 in melanoma cells decreases
melanoma invasiveness (Rodriguez et al., 2008). Our data link
oncogenic B-RAF to the Tbx3/E-cadherin cascade and confirm
that Tbx3 and B-RAFV600E silencing suppress melanoma
invasion through matrigel. The importance of the B-RAF/
Tbx3/E-cadherin network is further highlighted by several
studies that show independently that E-cadherin loss and
increased Tbx3 are associated with the progression of
melanoma, invasiveness, and poor prognosis (Hoek et al.,
2004; Tucci et al., 2007; Kreizenbeck et al., 2008; Rodriguez
et al., 2008; Mowla et al., 2010). It is not surprising that
E-cadherin
shRNATBX3 3TBX3 2Control
Co
ntr
ol
Co
ntr
ol
Co
ntr
ol
B-R
AF
V6
00
E
B-R
AF
V6
00
E
B-R
AF
V6
00
E
B-RAF
TBX3
p-ERK
ERK
Actin
Figure 5. B-RAF mediates the regulation of E-cadherin through Tbx3.
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was immunoblotted for the indicated proteins. This figure is compiled
from duplicate immunoblots. p-ERK, phosphorylated extracellular
signal–regulated kinase.
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Figure 6. B-RAFV600E promotes melanoma cell invasion. The V600E B-RAF-
mutant allele or Tbx3 were specifically silenced in the NM176 and ME1042
melanoma cell lines for 5 days. The invasion of melanoma cells was
determined by transwell matrigel invasion assays and is presented as relative
invasion compared with control silenced melanoma cells. Knockdown of
BRAFV600E and Tbx3 induced a significant (**Po0.05) or near significant
(*P¼0.05) decrease in cell invasion (P-values: NM176 V600E: 0.003, Tbx3:
0.0007; ME1042 V600E: 0.04, and Tbx3: 0.05). shRNA, short hairpin RNA.
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E-cadherin levels were generally low in our tumor samples
and thus did not correlate with B-RAF mutation status.
E-cadherin loss is critical for metastasis, and although
we have provided evidence that B-RAFV600E-induced Tbx3
represses E-cadherin expression, E-cadherin promoter
silencing (Tsutsumida et al., 2004) and expression of
alternate transcriptional repressors (Poser et al., 2001;
Kuphal and Bosserhoff, 2011) have also been reported in
melanoma and may account for the low E-cadherin levels in
tumors without mutant B-RAF.
Although we found no evidence that other transcriptional
repressors of E-cadherin, including SLUG and SNAIL, partici-
pated in B-RAFV600E-mediated repression of E-cadherin in
melanocytes, this does not preclude their involvement. For
instance, our microarray analyses did not yield high signal
data for the SNAIL transcript, which is a predicted B-RAFV600E
target (Lin et al., 2010) and may contribute to the suppression
of E-cadherin in B-RAFV600E-positive melanoma cell lines
(Poser et al., 2001). Thus, although we do not exclude the
involvement of other E-cadherin regulators, our data indicate
that Tbx3 is a critical mediator of the transcriptional repression
of E-cadherin by oncogenic B-RAF.
It is also worth noting that Tbx3 may prevent the onset of
senescence through its ability to repress the expression of the
p16INK4a, p14ARF, and p21Waf1 tumor suppressors
(Brummelkamp et al., 2002; Hoogaars et al., 2008; Mowla
et al., 2010). Nevertheless, the expression of oncogenic
B-RAFV600E in human melanocytes promotes senescence that
is associated with increased levels of p16INK4a (Scurr et al.,
2010) despite Tbx3 accumulation. This most likely reflects the
complex network of the regulatory and negative feedback
pathways activated in response to oncogenic stimulation, and
this network not only favors p16INK4a accumulation and
enforces proliferative arrest in primary cells, but also primes
damaged cells for transformation. Thus, the combined loss
of p16INK4a and the induced accumulation of Tbx3 by
B-RAFV600E may favor proliferation and transformation of
melanocytes.
In conclusion, we report that B-RAFV600E represses E-cad-
herin in melanocytes and this is consistent with data showing
that B-RAFV600E contributes to the EMT of transformed cells
(Minoo et al., 2007; Riesco-Eizaguirre, 2009; Lin et al., 2010).
We show that B-RAF induces the transcriptional repressor,
Tbx3, which results in diminished E-cadherin expression in
human melanocytes and increased invasiveness of B-RAFV600E-
mutant melanoma cells. These results highlight a key role of
Tbx3, which is commonly upregulated in melanomas, in
enhancing B-RAF-dependent melanoma progression and
suggest that inhibiting Tbx3 expression or activity may
represent a therapeutic target downstream of B-RAF.
MATERIALS AND METHODS
Cell culture and lentiviral transduction
Primary human dermal melanocytes (Cell Applications, San Diego,
CA) were cultured as reported previously (Haferkamp et al., 2009;
Scurr et al., 2010). Melanoma cell lines NM39, NM176, NM179, Sk-
Mel28, ME1042, WMM1175, and 501mel were cultured in DMEM
media with 10% fetal calf serum. Cells were treated with 10mm
Vemurafinib (PLX4032; Selleckchem, Houston, TX) for 2 days.
Lentiviral particles were generated and used to transduce cells as
reported previously (Haferkamp et al., 2009; Scurr et al., 2010). The
following shRNA sequences were cloned into pSIH1-H1-copGFP to
produce lentiviral particles: TBX3 2: 50-GATCCCTGCCTATAGAGAT
ATATTCACTTCCTGTCAGATGAATATATCTCTATAGGCATT-30, TBX
3 3: 50-GATCCGCTACAGAGAAATCTCGATCTTCCTGTCAGAATCG
AGATTTCTCTGTAGCTTTTTG-30, B-RAFV600E: 50-GATCCGCTACAG
AGAAATCTCGATCTTCCTGTCAGAATCGAGATTTCTCTGTAGCTTT
TTG-30 or control shRNA (no homology to any known human
transcript): 50-GATCCTTAGAGGCGAGCAAGACTACTTCCTGTCAG
ATAGTCTTGCTCGCCTCTAATTTTTG-30.
Immunoblotting
For detection of E-cadherin, cells were harvested with EDTA (2 mM in
phosphate-buffered saline). Equal amounts of total cellular proteins
(30–50mg), extracted at 4 1C with RIPA lysis buffer containing
protease inhibitors (Roche, Mannheim, Germany) and phosphatase
inhibitors (Roche), were resolved on 12% SDS-polyacrylamide gels,
transferred to Immobilon-P membranes (Millipore, Bedford, MA), and
probed with antibodies against E-cadherin (SHE78-7, Zymed, San
Francisco, CA), total ERK (137F5, Cell Signaling, Beverly, MA),
phosphorylated ERK (E-4, Santa Cruz Biotechnology, Santa Cruz,
CA), Tbx3 (ZMD.569, Zymed), endogenous B-RAF (L12G7, Cell
Signaling), and b-actin (AC-74, Sigma-Aldrich, St Louis, MO). MYC-
tagged B-RAF was detected with anti-MYC (A-14, Santa Cruz
Biotechnology).
qRT-PCR
Total RNA was extracted from melanocytes using TRI Reagent (Sigma)
with an additional purification step with RNAeasy kits (QIAGEN,
Valencia, CA). Samples were collected from two separate experi-
ments, and each sample amplified in duplicate in at least two
independent experiments. RNA (1mg) was used for complementary
DNA synthesis using SuperScript First-Strand Synthesis System for
RT-PCR (Invitrogen) with the supplied Oligo(dT)20 primer. qRT-PCR
products were amplified in 25ml from 2ml complementary DNA with
SYBR-Green incorporation (Power SYBR-Green PCR Master Mix,
Applied Biosystems, Warrington, UK) using a Corbett Rotorgene3000
(Corbett Research, Mortlake, NSW, Australia) and a final concentra-
tion of 0.3mM of qRT-PCR primers: E-cadherin forward (fwd): 50-
TGAAGGTGACAGAGCCTCTGGAT-30 and E-cadherin reverse (rev):
50-TGGGTGAATTCGGGCTTGTT-30 (Tsai et al., 2002); Tbx3 fwd: 50-
CGAAATGCCAAAGAGGATGT-30 and Tbx3 rev: 50-GAATTCAGTTT
CGGGGAACA-30 (note that this primer combination is known
to amplify two splice variants of TBX3; Lee et al., 2007);
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) fwd: 50-CTCT
CTGCTCCTCCTGTTCGAC-30 and GAPDH rev: 50-TGAGCGATGTG
GCTCGGCT-30; and TBP (TATA box protein) fwd: 50-TGCACAGGAG
CCAAGAGTGAA-30 and TBP rev: 50-CACATCACAGCTCCCCACC
A-30. Melting curve analysis and agarose gel separation ensured
product specificity. Relative gene expression was calculated from a
standard curve included with each run. Expression data were norma-
lized separately against the housekeeping genes GAPDH and TBP,
which were not affected by B-RAFV600E expression. Gene expression
levels of B-RAFV600E-expressing melanocytes are presented as fold
change in comparison with expression levels derived from melano-
cytes only expressing copGFP control, which was set at 1.
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RNA extraction and microarray gene expression analysis
Total RNA was extracted from melanocytes or from 10 to 20 mg of
fresh-frozen, homogenized tumor sample with Trizol (Invitrogen Life
Technologies, Carlsbad, CA). Chloroform was added and after
spinning the upper phase was mixed with 70% ethanol and RNA
was further purified with an RNeasy kit with DNase I digestion. Then,
250 ng total RNA (RNA integrity number: 9–10) was amplified and
labeled with biotin (Illumina TotalPrep RNA amplification kit;
Ambion, Austin, TX). Gene expression analysis was performed using
the Sentrix HumanRef-6 v.3.0 Expression BeadChip (Illumina, San
Diego, CA) and BeadStation system from Illumina according to the
manufacturer’s instructions.
For analysis, average signal intensities were background subtracted
and normalized using the cubic spline function in GenomeStudio and
the Illumina Custom function was used to assign a differential
expression score and P-value to each gene. Transcripts with detection
and differential expression Po0.01 were considered significantly
different. The Metacore analysis software package, version 6.8
(Thomson Reuters, Carlsbad, CA), was used to identify gene ontology
groups associated with oncogenic B-RAF signaling in melanocytes.
For tumor samples (stage III melanoma lymphnode metastasis), the
expression of Tbx3 and E-cadherin (CDH1) were assessed in correla-
tion to their B-RAF mutation status in a univariate analysis by logistic
regression. Scatter plots were used to illustrate the distribution of gene
expression by B-RAF mutation status (tumors with other known
mitogen-activated protein kinase pathway mutations as determined
using the Sequenom (Sequenom, Herston, Qld, Australia) OncoCarta
panel of 19 oncogenes and 238 mutations were excluded from this
analysis). Medians and interquartile ranges were applied to summarize
the distributions, and the Mann–Whitney test was used to determine
the differences between the B-RAF wild-type and B-RAFV600E-mutant
populations.
Promoter reporter assays
A total of 200 ng of the human Tbx3 promoter ( 249 to þ 168),
cloned into the luciferase promoter reporter vector pGL3-basic or
vector alone, was transfected into 501mel cells with 25 or 100 ng of
wild-type or V600E Myc epitope-tagged B-RAF expression vector.
Extracts were processed and assayed for luciferase. Western probing
for the Myc-tag of B-RAF and total ERK as a loading control confirmed
similar expression of the B-RAF constructs.
Transwell matrigel invasion assays
Matrigel invasion chambers (BD Biosciences, Bedford, MA) were
rehydrated for 2 hours with low serum (0.1% fetal calf serum) DMEM.
5 104 melanoma cells transduced with Tbx3 shRNA 3, B-RAFV600E
shRNA, or control shRNA for 5 days and suspended in low-serum
media were added to each 24-well insert, and media containing 10%
fetal calf serum was added to the bottom chamber. Approximately
24 hours after seeding, the invading melanoma cells were quantified
by Diff Quick stain (Lab aids, Narabeen, Australia) and microscopy
for cells adhering to the bottom of the membrane. As some melanoma
cell lines grow in suspension, we also tested cells that had invaded
into media in the bottom chamber. The latter were harvested and
spiked with 2 105 HEK293T cells and the number of copGFP-
expressing transduced melanoma cells per 5 104 unstained
HEK293T cells was determined by FACS analysis and normalized
on the input. ME1042 produced a negligible proportion of bottom
chamber suspension cells (o4% of membrane-bound control cells)
and these were not included in calculating relative invasion, whereas
NM176 suspension cells (448% of membrane bound control cells)
were included in calculating the relative invasion. Significance of the
decrease in invasion was determined by Student’s t-test.
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